Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 17/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29716182 | 0.95 | PDCD1 (0.42) | PDCD1CD274GAA | |
| SCHEMBL21621006 | 0.95 | PDCD1 (0.42) | PDCD1CD274GAA | |
| SCHEMBL22966491 | 0.95 | PDCD1 (0.42) | PDCD1CD274GAAHDAC3HDAC1 | |
| SCHEMBL21616705 | 0.94 | PDCD1 (0.42) | PDCD1CD274GAAHDAC3HDAC1 | |
| SCHEMBL21616699 | 0.94 | PDCD1 (0.53) | PDCD1CD274HDAC3HDAC1HDAC6 | |
| SCHEMBL21621008 | 0.94 | PDCD1 (0.43) | PDCD1CD274GAAHDAC3HDAC1 | |
| SCHEMBL29716258 | 0.94 | PDCD1 (0.43) | PDCD1CD274GAAHDAC3HDAC1 | |
| SCHEMBL21451812 | 0.93 | PDCD1 (0.41) | PDCD1CD274GAAHDAC3HDAC1 | |
| SCHEMBL21451811 | 0.93 | PDCD1 (0.42) | PDCD1CD274GAAHDAC3HDAC1 | |
| SCHEMBL21620986 | 0.92 | PDCD1 (0.42) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2019192506-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040118-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | PDCD1 409/4885CD274 148/4885GAA 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.